A review.This article discusses about perspective on the origin, resistance, and spread of the emerging human fungal pathogen Candida auris.Although antifungal resistance remains a key feature of most C. auris infections, relatively little is known about resistance mechanisms in C. auris compared to those of other human fungal pathogens.

2019-04-01·Antimicrobial Agents and Chemotherapy2区 · 医学

In VitroActivity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains ofCandida glabrata,Candida auris,Cryptococcus neoformans, andPneumocystisspp

2区 · 医学

Article

作者: Collins, M. ; Vikina, D. ; Tetz, V. ; Tetz, G.

bioRxiv, Microbiology

In vitro activity of a novel antifungal compound, MYC-053, against clinically significant antifungal-resistant strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp

作者: Collins, M. ; Tetz, G. ; Vikina, D. ; Tetz, V.

An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients.The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogens Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.MYC-053 was equally effective against the susceptible control strains, clin. isolates, and resistant strains, with the min. inhibitory concentrations (MIC) of 0.125-4.0μg/mL.Notably, unlike other antifungal compounds, MYC-053 was effective against Pneumocystis isolates.MYC-053 was highly effective against preformed 48-h-old yeast biofilms, with the minimal biofilm eradication concentrations equal to 1-4 times MIC.The compound was not cytotoxic against L2 and A549 cell lines at concentrations over 100μg/mL.Further, it possessed no apparent hemolytic activity up to 1000μg/mL (the highest concentration tested).Overall, these data indicated that MYC-053 has a broad therapeutic window and may be developed into a promising antifungal agent for the treatment and prevention of invasive fungal infections caused by yeasts and yeast-like fungi in neutropenic patients.

100 项与 MYC-053 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
念珠菌病	临床前	美国	National Institutes of Health	-
念珠菌病	临床前	美国	TGV-Health, Inc.	-
隐球菌病	临床前	美国	National Institutes of Health	-
隐球菌病	临床前	美国	TGV-Health, Inc.	-